Vancouver, British Columbia–(Newsfile Corp. – May 29, 2020) – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or “the Company”) is providing an update on the status of the filing of its interim financial statements and accompanying management’s discussion and analysis, and related CEO and CFO certifications for the three month period ended March 31, 2020 (collectively, the “Q1 Filings”).
On March 18, 2020, the Canadian Securities Administrators announced that they will provide all issuers with a 45-day filing extension for filings required on or before June 1, 2020 in light of recent COVID-19 developments and their impact on market participants. iCo will rely on this exemption to allow it to delay the filing of its Q1 Filings required by Sections 4.4 and 5.1(2) of National Instrument 51-102 by May 30, 2020.
The Company expects to file the Q1 Filings by and no later than July 13, 2020. In the interim, management and other insiders of the Company are subject to a trading black-out policy that reflects the principles in Section 9 of National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions.
iCo confirms that since the filing of its annual financial statements for the year ended December 31, 2019, there have been no material business developments other than those disclosed through news releases.
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.
For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements included in this press release may be considered “forward-looking information” within the meaning of applicable securities laws. Forward-looking information can be identified by words such as: “anticipate”, “intend”, “plan”, “goal”, “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include statements relating to the anticipated business plans and timing of future activities of the Company and the timing of the filing of the Q1 Filings. All forward-looking statements are based on iCo’s current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospectus, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based only on information currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
iCo Therapeutics Inc.
+1 (604) 800-9860
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/56824